Explore >> Select a destination
|
You are here 
|
changingtimes.media | ||
| | | | |
www.cancer.gov
|
|
| | | | | The success of COVID-19 mRNA vaccines could accelerate research on mRNA vaccines to treat cancer. Read about the progress of mRNA cancer vaccines. | |
| | | | |
www.covidtruths.co.uk
|
|
| | | | | SPEAKERS Reiner Fuellmich, Dr David Martin, Prof Martin Schwab, Dr Wolfgang Wodarg, Viviane Fischer Reiner Fuellmich 00:00 Sorry, I have kept you waiting. It's my fault. Are you still there? Dr David Martin 00:04 Yes, I am. Reiner Fuellmich 00:05 Oh, great. Nice to see you again. Dr David MartinContinue Reading | |
| | | | |
www.nature.com
|
|
| | | | | Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. Based on 78 vaccine efficacy or effectiveness (VE) data from 49 studies and 1,984,241 SARS-CoV-2 sequences collected from 31 regions, we analyzed the relationship between genetic distance (GD) of circulating viruses against the vaccine strain and VE against symptomatic in... | |
| | | | |
jameslyonsweiler.com
|
|
| | | Immunization with inactivated Middle East Respiratory Syndrome coronavirusvaccineleads tolungimmunopathology on challenge with live virus. "Lungmononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in thevaccinegroups. Inactivated MERS-CoVvaccineappears to carry a hypersensitive-typelungpathology risk from MERS-CoV infection that is... | ||
